Data Insights

Nivolumab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Metastatic Uveal Melanoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Relapsed Multiple Myeloma

Data Insights

Nivolumab by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Refractory Multiple Myeloma

Data Insights

Nivolumab by Ono Pharmaceutical for Mantle Cell Lymphoma: Likelihood of Approval

Nivolumab is under clinical development by Ono Pharmaceutical and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Mantle Cell Lymphoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Glioblastoma Multiforme (GBM)

Data Insights

Nivolumab by Bristol-Myers Squibb for T-Cell Lymphomas: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in T-Cell Lymphomas

Data Insights

Nivolumab by Bristol-Myers Squibb for Pleomorphic Liposarcoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Pleomorphic Liposarcoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Angiosarcoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Angiosarcoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Chondrosarcoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Chondrosarcoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pediatric Diffuse Intrinsic Pontine Glioma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Pediatric Diffuse Intrinsic Pontine Glioma

Data Insights

Nivolumab by Bristol-Myers Squibb for High-Grade Glioma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in High-Grade Glioma

Data Insights

Nivolumab by Bristol-Myers Squibb for Neuroblastoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Neuroblastoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Non-Small Cell Lung Carcinoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Non-Small Cell Lung Carcinoma

Data Insights

Nivolumab by Bristol-Myers Squibb for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in B-Cell Non-Hodgkin Lymphoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Merkel Cell Carcinoma: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Merkel Cell Carcinoma

Data Insights

Nivolumab by Bristol-Myers Squibb for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Metastatic Adenocarcinoma of The Pancreas

Data Insights

Nivolumab by Bristol-Myers Squibb for Prostate Cancer: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Prostate Cancer

Data Insights

Nivolumab by Bristol-Myers Squibb for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma)....

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Basal Cell Carcinoma (Basal Cell Epithelioma)

Data Insights

Nivolumab by Bristol-Myers Squibb for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Nivolumab by Bristol-Myers Squibb for Skin Cancer: Likelihood of Approval

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Skin Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Skin Cancer